Similarly, Praxbind (idarucizumab) 5 g IV is recommended for dabigatran-associated major bleeding and aPCC 50 units/kg IV is suggested if idarucizumab is unavailable. If andexanet alfa is not available, treatment with 4F-PCC 2,000 units is suggested. Ī 2019 guidance document from the Anticoagulation Forum suggests treatment with andexanet alfa in patients with rivaroxaban-associated or apixaban-associated major bleeding in whom a reversal agent is warranted. However, since Andexxa® (andexanet alfa) was not approved at time of the statement's publication, it was not mentioned in this guideline. If the intracranial hemorrhage occurred within 3-4 half-lives of ingestion, then Kcentra® (4-factor prothrombin complex concentrate ) 50 units/kg or activated PCC (aPCC) 50 units/kg is recommended. A 2016 guidance statement from the Neurocritical Care Society and the Society of Critical Care Medicine suggest activated charcoal 50 g to intubated intracranial hemorrhage patients presenting within 2 hours of ingestion of an oral factor Xa inhibitor.
0 Comments
Leave a Reply. |